Investigating how MALT1 affects the immune environment in aggressive breast cancer.
Role of MALT1 in regulating the breast cancer immune microenvironment
This study is looking at how a protein called MALT1 affects the immune system and tumor growth in triple-negative breast cancer, especially in African-American and Hispanic women, to find new ways to treat this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11143952 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), which is particularly prevalent among African-American and Hispanic women. The study aims to explore the role of MALT1, a protein involved in cancer signaling, in shaping the immune microenvironment of TNBC. By understanding how MALT1 influences tumor behavior and immune response, the researchers hope to identify new therapeutic targets that could lead to more effective treatments for this challenging cancer type. Patients may be involved in studies that assess the impact of targeting MALT1 on tumor progression and immune response.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with triple-negative breast cancer, particularly those who are African-American or Hispanic.
Not a fit: Patients with other types of breast cancer or those who do not have triple-negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve treatment outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting similar signaling pathways in cancer, suggesting that this approach may yield beneficial results.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lucas, Peter C — Mayo Clinic Rochester
- Study coordinator: Lucas, Peter C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.